The recently established CERD represents an important national and international reference center for HTA research and Drug Regulatory Affairs. CERD will strengthen an already ongoing network among Experts and KOL, aiming to create a solid task force able to develop research projects and attract relative funds.

CERD members have high quality, solid, long experienced background and expertise in Clinical Pharmacology, Regulatory Affairs, HTA and Pharmacoeconomics.

CERD activities are devoted to either research and educational activity. CERD research activities are focused on: a) HTA; b) monitoring of biotechnological drugs; c) monitoring and methodologies of evaluation of innovative drugs; d) monitoring and consulting of off-label drug use; e) methodologies to control pharmaceutical expenditure.

Within the continuous medical education (CME) activities, CERD participates the annual “Conferenza Nazionale sulla Farmaceutica” and the Master Degrees in “Drug Regulatory Affairs” and “Clinical trial’s Governance” which are active since years at the Department of Biomedical and Biotechnological Sciences, University of Catania.

Approved Cellular and Gene Therapy Products (Jul 30, 2018)

1.ALLOCORD (HPC Cord Blood)
2. LAVIV (Azficel-T)
3. MACI (Autologous Cultured Chondrocytes on a Porcine Collagen Membrane)
4. CLEVECORD (HPC Cord Blood)
5. GINTUIT (Allogeneic Cultured Keratinocytes and Fibroblasts in Bovine Collagen)
6. HEMACORD (HPC, cord blood)
7. DUCORD, HPC Cord Blood
8. HPC, Cord Blood
10. HPC, Cord Blood - LifeSouth
11. HPC, Cord Blood - Bloodworks
12. IMLYGIC (talimogene laherparepvec)
13. KYMRIAH (tisagenlecleucel)
14. LUXTURNA
15. PROVENGE (sipuleucel-T)
16. YESCARTA (axicabtagene ciloleucel)